Correlation between time-dependent inhibition of human farnesyl pyrophosphate synthase and blockade of mevalonate pathway by nitrogen-containing bisphosphonates in cultured cells

Biochemical and Biophysical Research Communications

Volumn 407, Issue 4, 2011, Pages 663-667

  Räikkönen, Johanna ^a,b   Taskinen, Markku ^a,b   Dunford, James E ^c   Mönkkönen, Hannu ^a,b   Auriola, Seppo ^a,b   Mönkkönen, Jukka ^a,b  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b Biocenter Kuopio   (Finland)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

ApppI; Bisphosphonate; Bisphosphonate analog; Farnesyl pyrophosphate synthase; Isomerization constant; Isopentenyl pyrophosphate

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; FARNESYL DIPHOSPHATE; FARNESYLPYROPHOSPHATE SYNTHASE; ISOPENTENYL DIPHOSPHATE; MEVALONIC ACID; NE 21650; NE 58027; NE 58043; NE 58062; NE 97220; NITROGEN; RISEDRONIC ACID; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ARTICLE; BIOSYNTHESIS; CANCER CELL CULTURE; CELL CULTURE; CELL FREE SYSTEM; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DRUG POTENCY; HUMAN; HUMAN CELL; ISOMERIZATION; MOLECULAR MECHANICS; PRIORITY JOURNAL; TIMED DRUG RELEASE;

CELLS, CULTURED; DIMETHYLALLYLTRANSTRANSFERASE; DIPHOSPHONATES; HUMANS; MEVALONIC ACID; NITROGEN; TIME FACTORS;

EID: 79954989286     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.03.070     Document Type: Article

References (24)

1. Roux C., Dougados M. Treatment of patients with Paget's disease of bone. Drugs 1999, 58:823-830.
2. Delmas P.D. Treatment of postmenopausal osteoporosis. Lancet 2002, 359:2018-2026.
3. Diel I.J., Solomayer E.F., Bastert G. Bisphosphonates and the prevention of metastasis: first evidences from preclinical and clinical studies. Cancer 2000, 88:3080-3088.
4. Coleman R.E. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat. Rev. 2001, 27:165-176.
5. Stresing V., Daubine F., Benzaid I., Mönkkönen H., Clezardin P. Bisphosphonates in cancer therapy. Cancer Lett. 2007, 257:16-35.
6. Gnant M., Mlineritsch B., Schippinger W., Luschin-Ebengreuth G., Postlberger S., Menzel C., Jakesz R., Seifert M., Hubalek M., Bjelic-Radisic V., Samonigg H., Tausch C., Eidtmann H., Steger G., Kwasny W., Dubsky P., Fridrik M., Fitzal F., Stierer M., Rucklinger E., Greil R., Marth C. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N. Engl. J. Med. 2009, 360:679-691. ABCSG-12 Trial Investigators.
7. van Beek E., Pieterman E., Cohen L., Lowik C., Papapoulos S. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem. Biophys. Res. Commun. 1999, 264:108-111.
8. Bergstrom J.D., Bostedor R.G., Masarachia P.J., Reszka A.A., Rodan G. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch. Biochem. Biophys. 2000, 373:231-241.
9. Luckman S.P., Hughes D.E., Coxon F.P., Graham R., Russell G., Rogers M.J. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J. Bone Miner. Res. 1998, 13:581-589.
10. Mönkkönen H., Auriola S., Lehenkari P., Kellinsalmi M., Hassinen I.E., Vepsalainen J., Mönkkönen J. A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonates. Br. J. Pharmacol. 2006, 147:437-445.
11. Jauhiainen M., Mönkkönen H., Räikkönen J., Mönkkönen J., Auriola S. Analysis of endogenous ATP analogs and mevalonate pathway metabolites in cancer cell cultures. J. Chromatogr. B Biomed. Sci. Appl. 2009, 877:2967-2975.
12. Mönkkönen H., Kuokkanen J., Holen I., Evans A., Lefley D., Jauhiainen M., Auriola S., Mönkkönen J. Bisphosphonate-induced ATP analog formation and its effect on inhibition of cancer cell growth. Anticancer Drugs 2008, 19:391-399.
13. Mönkkönen H., Ottewell P.D., Kuokkanen J., Mönkkönen J., Auriola S., Holen I. Zoledronic acid-induced IPP/ApppI production in vivo. Life Sci. 2007, 81:1066-1070.
14. Räikkönen J., Mönkkönen H., Auriola S., Mönkkönen J. Mevalonate pathway intermediates downregulate zoledronic acid-induced isopentenyl pyrophosphate and ATP analog formation in human breast cancer cells. Biochem. Pharmacol. 2010, 79:777-783.
15. Räikkönen J., Crockett J.C., Rogers M.J., Mönkkönen H., Auriola S., Mönkkönen J. Zoledronic acid induces formation of a pro-apoptotic ATP analogue and isopentenyl pyrophosphate in osteoclasts in vivo and in MCF-7 cells in vitro. Br. J. Pharmacol. 2009, 157:427-435.
16. Mitrofan L., Pelkonen J., Mönkkönen J. The level of ATP analogue and isopentenyl pyrophosphate correlates with zoledronic acid-induced apoptosis in cancer cells in vitro. Bone 2009, 45:1153-1160.
17. Kavanagh K.L., Guo K., Dunford J.E., Wu X., Knapp S., Ebetino F.H., Rogers M.J., Russell R.G., Oppermann U. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc. Natl. Acad. Sci. USA 2006, 103:7829-7834.
18. Rondeau J.M., Bitsch F., Bourgier E., Geiser M., Hemmig R., Kroemer M., Lehmann S., Ramage P., Rieffel S., Strauss A., Green J.R., Jahnke W. Structural basis for the exceptional in vivo efficacy of bisphosphonate drugs. ChemMedChem 2006, 1:267-273.
19. Dunford J.E., Kwaasi A.A., Rogers M.J., Barnett B.L., Ebetino F.H., Russell R.G., Oppermann U., Kavanagh K.L. Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase. J. Med. Chem. 2008, 51:2187-2195.
20. Schloss J.V. Significance of slow-binding enzyme inhibition and its relationship to reaction-intermediate analogues. Acc. Chem. Res. 1988, 21:348-353.
21. Mönkkönen H., Tormalehto S., Asunmaa K., Niemi R., Auriola S., Vepsäläinen J., Mönkkönen J. Cellular uptake and metabolism of clodronate and its derivatives in Caco-2 cells: a possible correlation with bisphosphonate-induced gastrointestinal side-effects. Eur. J. Pharm. Sci. 2003, 19:23-29.
22. Dunford J.E., Thompson K., Coxon F.P., Luckman S.P., Hahn F.M., Poulter C.D., Ebetino F.H., Rogers M.J. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J. Pharmacol. Exp. Ther. 2001, 296:235-242.
23. Thompson K., Dunford J.E., Ebetino F.H., Rogers M.J. Identification of a bisphosphonate that inhibits isopentenyl diphosphate isomerase and farnesyl diphosphate synthase. Biochem. Biophys. Res. Commun. 2002, 290:869-873.
24. Hahn F.M., Xuan J.W., Chambers A.F., Poulter C.D. Human isopentenyl diphosphate: dimethylallyl diphosphate isomerase: overproduction, purification, and characterization. Arch. Biochem. Biophys. 1996, 332:30-34.